Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1077-1086 |
| Number of pages | 10 |
| Journal | Antiviral Therapy |
| Volume | 15 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Jan 2010 |
Keywords
- adult
- article
- cardiovascular risk
- diabetes mellitus
- disease association
- disease course
- female
- heart infarction
- hepatitis B
- hepatitis C
- human
- Human immunodeficiency virus infection
- major clinical study
- male
- outcome assessment
- priority journal
- risk factor
- stroke
- Adult
- Australia
- Cohort Studies
- Europe
- Female
- Hepatitis B
- Hepatitis B Antibodies
- Hepatitis C
- Hepatitis C Antibodies
- HIV Infections
- Humans
- Male
- Multivariate Analysis
- Myocardial Infarction
- Poisson Distribution
- Prospective Studies
- Regression Analysis
- Risk Factors
- Stroke
- Substance Abuse, Intravenous
- Time Factors
- United States
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. / Weber, R.; Sabin, C.; Reiss, P.; De Wit, S.; Worm, S.W.; Law, M.; Dabis, F.; Monforte, A.D.; Fontas, E.; El-Sadr, W.; Kirk, O.; Rickenbach, M.; Phillips, A.; Ledergerber, B.; Lundgren, J.; Torres, Ferran.
In: Antiviral Therapy, Vol. 15, No. 8, 01.2010, p. 1077-1086.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.
AU - Weber, R.
AU - Sabin, C.
AU - Reiss, P.
AU - De Wit, S.
AU - Worm, S.W.
AU - Law, M.
AU - Dabis, F.
AU - Monforte, A.D.
AU - Fontas, E.
AU - El-Sadr, W.
AU - Kirk, O.
AU - Rickenbach, M.
AU - Phillips, A.
AU - Ledergerber, B.
AU - Lundgren, J.
AU - Torres, Ferran
N1 - Cited By :29 Export Date: 17 February 2022 CODEN: ANTHF Correspondence Address: Weber, R.; Division of Infectious Diseases, , Zurich, Switzerland; email: infweb@usz.uzh.ch Chemicals/CAS: Hepatitis B Antibodies; Hepatitis C Antibodies Funding details: National Institute of Allergy and Infectious Diseases, NIAID, U01AI042170, U01AI046362 References: Bedimo, R., Ghurani, R., Nsuami, M., Lipid abnormalities in HIV/hepatitis C virus-coinfected patients (2006) HIV Med, 7, pp. 530-536; Collazos, J., Mayo, J., Ibarra, S., Hyperlipidemia in HIV-infected patients: The protective effect of hepatitis C virus co-infection (2003) AIDS, 17, pp. 927-929; Floris-Moore, M., Howard, A.A., Lo, Y., Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men (2007) AIDS Patient Care STDS, 21, pp. 479-491; Dai, C.Y., Chuang, W.L., Ho, C.K., Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study (2008) J Hepatol, 49, pp. 9-16; Reingold, J., Wanke, C., Kotler, D., Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: The fat redistribution and metabolic change in HIV infection (FRAM) study (2008) J Acquir Immune Defic Syndr, 48, pp. 142-148; Libby, P., Egan, D., Skarlatos, S., Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research (1997) Circulation, 96, pp. 4095-4103; Fabricant, C.G., Fabricant, J., Litrenta, M.M., Virus-induced atherosclerosis (1978) J Exp Med, 148, pp. 335-340; Muhlestein, J.B., Anderson, J.L., Hammond, E.H., Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model (1998) Circulation, 97, pp. 633-636; Mayr, M., Kiechl, S., Willeit, J., Infections, immunity, and atherosclerosis: Associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis (2000) Circulation, 102, pp. 833-839; Zhu, J., Nieto, F.J., Horne, B.D., Prospective study of pathogen burden and risk of myocardial infarction or death (2001) Circulation, 103, pp. 45-51; Zhu, J., Quyyumi, A.A., Norman, J.E., The possible role of hepatitis A virus in the pathogenesis of atherosclerosis (2000) J Infect Dis, 182, pp. 1583-1587; Danesh, J., Collins, R., Peto, R., Chronic infections and coronary heart disease: Is there a link? (1997) Lancet, 350, pp. 430-436; O'Connor, S., Taylor, C., Campbell, L.A., Potential infectious etiologies of atherosclerosis: A multifactorial perspective (2001) Emerg Infect Dis, 7, pp. 780-788; Ludewig, B., Freigang, S., Jaggi, M., Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model (2000) Proc Natl Acad Sci U S A, 97, pp. 12752-12757; Nicoletti, A., Kaveri, S., Caligiuri, G., Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice (1998) J Clin Invest, 102, pp. 910-918; Class of antiretroviral drugs and the risk of myocardial infarction (2007) N Engl J Med, 356, pp. 1723-1735. , The DAD Study Group; Combination antiretroviral therapy and the risk of myocardial infarction (2003) N Engl J Med, 349, pp. 1993-2003. , The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group; Friis-Moller, N., Weber, R., Reiss, P., Cardiovascular disease risk factors in HIV patients -association with antiretroviral therapy. Results from the DAD study (2003) AIDS, 17, pp. 1179-1193; Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration (2008) Lancet, 371, pp. 1417-1426. , D:A:D Study Group; Ledergerber, B., Furrer, H., Rickenbach, M., Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study (2007) Clin Infect Dis, 45, pp. 111-119; De Wit, S., Sabin, C., Weber, R., Incidence and risk factors for new-onset diabetes in HIV-infected patients: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study (2008) Diabetes Care, 31, pp. 1224-1229; Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients (2008) AIDS, 22, pp. F17-F24. , The SMART/INSIGHT and DAD Study Groups; Hsue, P.Y., Hunt, P.W., Wu, Y., Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients (2009) AIDS, 23, pp. 2021-2027; Hsue, P.Y., Hunt, P.W., Schnell, A., Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis (2009) AIDS, 23, pp. 1059-1067; De Larranaga, G.F., Wingeyer, S.D., Puga, L.M., Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment (2006) Eur J Clin Microbiol Infect Dis, 25, pp. 98-103; Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study (2006) Arch Intern Med, 166, pp. 1632-1641. , The Data Collection on Adverse Events of Anti-HIV Drugs Study Group; Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents (1994) Circulation, 90, pp. 583-612; Sterne, J.A., White, I.R., Carlin, J.B., Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls (2009) BMJ, 338, pp. b2393; Hernan, M.A., Brumback, B., Robins, J.M., Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men (2000) Epidemiology, 11, pp. 561-570; Weber, R., Sabin, C.A., Reiss, P., Hepatitis virus co-infections and risk of diabetes mellitus and myocardial infarction in HIV-infected persons: The D:A:D Study 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA, , Abstract 1082; Ishizaka, N., Ishizaka, Y., Takahashi, E., Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening (2002) Lancet, 359, pp. 133-135; Ishizaka, Y., Ishizaka, N., Takahashi, E., Association between hepatitis C virus core protein and carotid atherosclerosis (2003) Circ J, 67, pp. 26-30; Fukui, M., Kitagawa, Y., Nakamura, N., Hepatitis C virus and atherosclerosis in patients with type 2 diabetes (2003) JAMA, 289, pp. 1245-1246; Vassalle, C., Masini, S., Bianchi, F., Evidence for association between hepatitis C virus seropositivity and coronary artery disease (2004) Heart, 90, pp. 565-566; Tien, P.C., Schneider, M.F., Cole, S.R., Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study (2009) AIDS, 23, pp. 1781-1784; Arcari, C.M., Nelson, K.E., Netski, D.M., No association between hepatitis C virus seropositivity and acute myocardial infarction (2006) Clin Infect Dis, 43, pp. e53-e56; Völzke, H., Schwahn, C., Wolff, B., Hepatitis B and C virus infection and the risk of atherosclerosis in a general population (2004) Atherosclerosis, 174, pp. 99-103; Butt, A.A., Xiaoqiang, W., Budoff, M., Hepatitis C virus infection and the risk of coronary disease (2009) Clin Infect Dis, 49, pp. 225-232; Freiberg, M.S., Cheng, D.M., Kraemer, K.L., The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals (2007) AIDS, 21, pp. 193-197; Bedimo, R., Westfall, A.O., Mugavero, M., Drechsler, H., Khanna, N., Saag, M., Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients (2010) HIV Med, 11, pp. 462-468; Ishizaka, N., Ishizaka, Y., Takahashi, E., Increased prevalence of carotid atherosclerosis in hepatitis B virus carriers (2002) Circulation, 105, pp. 1028-1030; Kiechl, S., Egger, G., Mayr, M., Chronic infections and the risk of carotid atherosclerosis: Prospective results from a large population study (2001) Circulation, 103, pp. 1064-1070; Momiyama, Y., Ohmori, R., Kato, R., Lack of any association between persistent hepatitis B or C virus infection and coronary artery disease (2005) Atherosclerosis, 181, pp. 211-213; Tong, D.Y., Wang, X.H., Xu, C.F., Hepatitis B virus infection and coronary atherosclerosis: Results from a population with relatively high prevalence of hepatitis B virus (2005) World J Gastroenterol, 11, pp. 1292-1296; Sung, J., Song, Y.M., Choi, Y.H., Hepatitis B virus seropositivity and the risk of stroke and myocardial infarction (2007) Stroke, 38, pp. 1436-1441; Petty, G.W., Duffy, J., Houston III, J., Cerebral ischemia in patients with hepatitis C virus infection and mixed cryoglobulinemia (1996) Mayo Clin Proc, 71, pp. 671-678; Delluc, A., Saadoun, D., Ghillani-Dalbin, P., Cryofibrinogen in patients with hepatitis C virus infection (2008) Am J Med, 121, pp. 624-631; Capra, F., De Maria, E., Lunardi, C., Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: A prognostic marker for responses to interferon treatment (2000) J Infect Dis, 181, pp. 425-431; Cacoub, P., Ghillani, P., Revelen, R., Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia (1999) J Hepatol, 31, pp. 598-603; Sumida, Y., Nakashima, T., Yoh, T., Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection (2000) J Hepatol, 33, pp. 616-622; Okuda, M., Li, K., Beard, M.R., Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein (2002) Gastroenterology, 122, pp. 366-375; Li, K., Prow, T., Lemon, S.M., Cellular response to conditional expression of hepatitis C virus core protein in Huh7 cultured human hepatoma cells (2002) Hepatology, 35, pp. 1237-1246; Sansonno, D., Tucci, F.A., Troiani, L., Increased serum levels of the chemokine CXCL13 and upregulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis (2008) Blood, 112, pp. 1620-1627; Guillevin, L., Mahr, A., Callard, P., Hepatitis B virus-associated polyarteritis nodosa: Clinical characteristics, outcome, and impact of treatment in 115 patients (2005) Medicine (Baltimore), 84, pp. 313-322; Agnello, V., Abel, G., Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia (1997) Arthritis Rheum, 40, pp. 2007-2015; Mason, A., Theal, J., Bain, V., Hepatitis B virus replication in damaged endothelial tissues of patients with extrahepatic disease (2005) Am J Gastroenterol, 100, pp. 972-976; Meade, T.W., Stirling, Y., Thompson, S.G., Carriers of hepatitis B surface antigen: Possible association between low levels of clotting factors and protection against ischaemic heart disease (1987) Thromb Res, 45, pp. 709-713; Marchesini, G., Ronchi, M., Forlani, G., Cardiovascular disease in cirrhosis - A point-prevalence study in relation to glucose tolerance (1999) Am J Gastroenterol, 94, pp. 655-662
PY - 2010/1
Y1 - 2010/1
N2 - Background: Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals. Methods: The prospective observational database of the D:A:D collaboration of 11 cohorts of HIV-infected individuals, including 212 clinics in Europe, the United States and Australia was used. Multivariate Poisson regression was used to assess the effect of HCV or HBV infection on the development of myocardial infarction after adjustment for potential confounders, including cardiovascular risk factors, diabetes mellitus and exposure to antiretroviral therapy. Results: Of 33,347 individuals, 517 developed a myocardial infarction over 157,912 person-years, with an event rate of 3.3 events/1,000 person-years (95% confidence interval [CI] 3.0-3.6). Event rates (95% CIs) per 1,000 person-years in those who were HCV- seronegative and HCV-seropositive were 3.3 (3.0-3.7) and 2.7 (2.2-3.3), respectively, and for those who were HBV-seronegative, had inactive infection or had active infection were 3.2 (2.8-3.5), 4.2 (3.1-5.2) and 2.8 (1.8-3.9), respectively. After adjustment, there was no association between HCV seropositivity (rate ratio 0.86 [95% CI 0.62-1.19]), inactive HBV infection (rate ratio 1.07 [95% CI 0.79-1.43]) or active HBV infection (rate ratio 0.78 [95% CI 0.52-1.15]) and the development of myocardial infarction. Conclusions: We found no association between HBV or HCV coinfection and the development of myocardial infarction among HIV-infected individuals. ©2010 International Medical Press.
AB - Background: Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals. Methods: The prospective observational database of the D:A:D collaboration of 11 cohorts of HIV-infected individuals, including 212 clinics in Europe, the United States and Australia was used. Multivariate Poisson regression was used to assess the effect of HCV or HBV infection on the development of myocardial infarction after adjustment for potential confounders, including cardiovascular risk factors, diabetes mellitus and exposure to antiretroviral therapy. Results: Of 33,347 individuals, 517 developed a myocardial infarction over 157,912 person-years, with an event rate of 3.3 events/1,000 person-years (95% confidence interval [CI] 3.0-3.6). Event rates (95% CIs) per 1,000 person-years in those who were HCV- seronegative and HCV-seropositive were 3.3 (3.0-3.7) and 2.7 (2.2-3.3), respectively, and for those who were HBV-seronegative, had inactive infection or had active infection were 3.2 (2.8-3.5), 4.2 (3.1-5.2) and 2.8 (1.8-3.9), respectively. After adjustment, there was no association between HCV seropositivity (rate ratio 0.86 [95% CI 0.62-1.19]), inactive HBV infection (rate ratio 1.07 [95% CI 0.79-1.43]) or active HBV infection (rate ratio 0.78 [95% CI 0.52-1.15]) and the development of myocardial infarction. Conclusions: We found no association between HBV or HCV coinfection and the development of myocardial infarction among HIV-infected individuals. ©2010 International Medical Press.
KW - adult
KW - article
KW - cardiovascular risk
KW - diabetes mellitus
KW - disease association
KW - disease course
KW - female
KW - heart infarction
KW - hepatitis B
KW - hepatitis C
KW - human
KW - Human immunodeficiency virus infection
KW - major clinical study
KW - male
KW - outcome assessment
KW - priority journal
KW - risk factor
KW - stroke
KW - Adult
KW - Australia
KW - Cohort Studies
KW - Europe
KW - Female
KW - Hepatitis B
KW - Hepatitis B Antibodies
KW - Hepatitis C
KW - Hepatitis C Antibodies
KW - HIV Infections
KW - Humans
KW - Male
KW - Multivariate Analysis
KW - Myocardial Infarction
KW - Poisson Distribution
KW - Prospective Studies
KW - Regression Analysis
KW - Risk Factors
KW - Stroke
KW - Substance Abuse, Intravenous
KW - Time Factors
KW - United States
UR - http://www.ncbi.nlm.nih.gov/pubmed/21149914
U2 - 10.3851/IMP1681
DO - 10.3851/IMP1681
M3 - Article
C2 - 21149914
VL - 15
SP - 1077
EP - 1086
JO - Antiviral Therapy
JF - Antiviral Therapy
SN - 1359-6535
IS - 8
ER -